Several protein tumor markers are currently approved for use in clinical practice, and some of the most common include human epidermal growth factor 2 (HER2/neu), estrogen receptor (ER), progesterone receptor (PR), prostate-specific antigen (PSA) and receptor tyrosine kinase (cKit) [8]. This evidence concerns the gene PGR and neoplasm.